Source-grounded facts extracted from Indivior Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Indivior Pharmaceuticals, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-05-13 meeting.
“4. To ratify the appointment of PricewaterhouseCoopers LLP US (PwC) as our independent registered public accounting firm for the fiscal year ending December 31, 2026: Votes For Votes Against Votes Abstained Broker Non-Votes 99,146,241 1,237,984 23,497 0”
Indivior Pharmaceuticals, Inc. shareholders approved Advisory vote on preferred frequency of say-on-pay votes at the 2026-05-13 meeting.
“3. To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers (Say-on-Frequency): Votes For 1 Year Votes For 2 Years Votes For 3 Years Votes Abstained Broker Non-Votes 91,848,954 21,701 1,032,941 34,100 7,470,026”
Indivior Pharmaceuticals, Inc. shareholders approved Advisory vote to approve compensation of named executive officers at the 2026-05-13 meeting.
“2. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement (Say-on-Pay): Votes For Votes Against Votes Abstained Broker Non-Votes 90,364,566 1,324,996 1,248,134 7,470,026”
Indivior Pharmaceuticals, Inc. shareholders approved Election of eight director nominees each to serve for a one-year term until 2027 Annual Meeting at the 2026-05-13 meeting.
“1. To elect eight director nominees, each to serve for a one-year term extending until our 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified: Nominee Votes For Votes Against Votes Abstained Broker Non-Votes Dr. David Wheadon 91,378,828 1,534,064 24,804 7,470,026 Joe Ciaffoni 92,834,811 76,839 26,046 7,470,026 Dr. Keith Humphreys 92,839,955 72,084 25,657 7,470,026 Tony Kingsley 92,839,469 72,503 25,724 7,470,026 Daniel Ninivaggi 87,545,032 5,366,849 25,815 7,470,026 Barbara Ryan 91,562,195 1,302,383 73,118 7,470,026 Mark Stejbach 92,838,962 72,847 25,887 7,470,026 Juliet Thompson 92,136,342 728,040 73,314 7,470,026”
Dr. Christian Heidbreder departed as Chief Scientific Officer at Indivior Pharmaceuticals, Inc..
“Effective June 1, 2026, Indivior Pharmaceuticals, Inc. (the "Company" or the "Registrant") will eliminate the position of Chief Scientific Officer.”
Indivior Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: revenue $317 million, net income $89 million, EPS $0.69 diluted earnings per share. Guidance raised.
“Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance • Q1’26 Total Net Revenue of $317 Million, Up 19% YoY • Q1’26 Total SUBLOCADE ® Net Revenue of $232 Million, Up 32% YoY • Q1’26 GAAP Net Income of $89 Million and Q1’26 Non-GAAP Net Income of $123 Million • Record”
Indivior Pharmaceuticals, Inc. issued convertible note to initial purchasers for $500,000,000 principal amount.
“Section 13(a) of the Exchange Act. ☐ Item 1.01. Entry Into a Material Definitive Agreement. Indenture On March 17, 2026, Indivior Pharmaceuticals, Inc. (the “ Company ”) issued $500,000,000 principal amount of its 0.625% Convertible Senior Notes due 2031 (the “ Notes ”; the “ Convertible Notes Offering ”). The Notes were issued pursuant to, and are governed by, an”
Indivior Pharmaceuticals, Inc. incurred convertible notes of $500,000,000 principal amount with U.S. Bank Trust Company, National Association at 0.625% per annum maturing March 15, 2031.
“On March 17, 2026, Indivior Pharmaceuticals, Inc. (the “ Company ”) issued $500,000,000 principal amount of its 0.625% Convertible Senior Notes due 2031 (the “ Notes ”; the “ Convertible Notes Offering ”).”
Indivior Pharmaceuticals, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $500,000,000 principal amount (effective 2026-03-17).
“On March 17, 2026, Indivior Pharmaceuticals, Inc. (the “ Company ”) issued $500,000,000 principal amount of its 0.625% Convertible Senior Notes due 2031”
Indivior Pharmaceuticals, Inc.: Adopted Global Code of Conduct and Code of Ethics for Senior Financial Officers (effective 2026-01-26).
“Effective January 26, 2026, Indivior U.S. adopted a Global Code of Conduct which applies to all directors, officers, and employees of Indivior U.S., and a Code of Ethics for Senior Financial Officers, each of which are substantially the same as those of Indivior U.K.”
Indivior Pharmaceuticals, Inc.: Adopted Bylaws in connection with U.S. Domestication.
“Indivior U.S. adopted Bylaws, a copy of which is attached hereto as Exhibit 3.2 (the “ Bylaws ”).”
Indivior Pharmaceuticals, Inc. amended First Amendment to Note Purchase Agreement with RBP Global Holdings Limited, Piper Sandler Finance LLC, as Administrative Agent and the lenders from time to time party thereto (effective 2026-01-26).
“Amendment to Note Purchase Agreement Effective January 26, 2026, following the effectiveness of the U.S. Domestication, RBP Global Holdings Limited, Piper Sandler Finance LLC, as Administrative Agent and the lenders from time to time party thereto entered into that certain First Amendment to Note Purchase Agreement with respect to the Note Purchase Agreement, dated as of November 4, 2024 (the “Note Purchase Agreement”)”
Indivior Pharmaceuticals, Inc. underwent a change of control involving Indivior PLC (closed 2026-01-23).
“ncorporation) (Commission File Number) (IRS Employer Identification No.) 10710 Midlothian Turnpike , Suite 125 North Chesterfield , VA 23235 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: 804 - 379-1040 Indivior PLC (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.”
Indivior Pharmaceuticals, Inc.: Amended and restated articles of association to add Article 136 for the purpose of facilitating the scheme of arrangement (effective 2025-12-11).
“On December 11, 2025 shareholders of Indivior PLC (the "Company" or the "Registrant") approved amended and restated articles of association (the “Amended Articles”). The amendments introduced a new Article 136 for the purpose of facilitating the scheme of arrangement as set out in the shareholder circular published on November 14, 2025 (the “Scheme of Arrangement”).”
Indivior Pharmaceuticals, Inc. announced a restructuring with charges of approximately $25 to $28 million affecting enterprise-wide.
“The Company expects pre-tax cash and non-cash asset charges of approximately $25 to $28 million resulting from the termination of certain contracts.”
Indivior Pharmaceuticals, Inc. announced a impairment with charges of approximately $21 to $27 million affecting enterprise-wide.
“The Company expects pre-tax cash and non-cash asset charges of approximately $21 to $27 million resulting from the write-downs of intangible assets and inventory.”
Indivior Pharmaceuticals, Inc. announced a restructuring with charges of approximately $15 to $21 million affecting real estate.
“The Company expects pre-tax cash and non-cash asset charges of approximately $15 to $21 million resulting from the consolidation and exit of certain real estate properties, including write-downs of leasehold improvements, fixed assets, and acceleration of leased property restoration costs.”
Indivior Pharmaceuticals, Inc. announced a restructuring with charges of approximately $33 to $37 million affecting enterprise-wide.
“The Company expects pre-tax employee severance and related employee exit charges of approximately $33 to $37 million, of which $17 million was recognized in the third quarter of 2025.”
Indivior Pharmaceuticals, Inc. announced a restructuring with charges of approximately $39 to $50 million of restructuring charges pre-tax, of which $27-$35 million will be cash affecting enterprise-wide (pre-tax employee severance and related employee exit charges of approximately $16 to $19 million).
“which will be recognized in the third quarter of 2025. As a result of this initial initiative related to Phase 1, the Company expects to recognize a total of approximately $39 to $50 million of restructuring charges pre-tax, of which $27-$35 million will be cash, and which are expected to be recognized in the third and fourth quarters of 2025. These”
Indivior Pharmaceuticals, Inc.: Amended articles of association to update provisions regarding general meetings, director elections, share sales, and primary listing references (effective 2025-05-08).
“On May 8, 2025, Indivior’s shareholders approved amendments to the Company’s articles of association effective upon the conclusion of the 2025 AGM.”
Mark Crossley departed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..
“Also, pursuant to his separation agreement, Mark Crossley stepped down as CEO of the Company and as a director.”
Joe Ciaffoni was appointed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..
“Following shareholder approval of the Company’s Directors’ Remuneration Policy, the Company and Joe Ciaffoni agreed that his employment as CEO would commence on May 8, 2025.”
Jo LeCouilliard departed as Non-Executive Director at Indivior Pharmaceuticals, Inc..
“Peter Bains and Jo LeCouilliard have decided not to stand for re-election at the Company’s Annual General Meeting.”
Peter Bains departed as Non-Executive Director at Indivior Pharmaceuticals, Inc..
“Peter Bains and Jo LeCouilliard have decided not to stand for re-election at the Company’s Annual General Meeting.”
Robert Schriesheim resigned as Independent Non-Executive Director at Indivior Pharmaceuticals, Inc..
“Robert Schriesheim notified the Board of his resignation therefrom on March 2, 2025 with immediate effect.”
Joe Ciaffoni was appointed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..
“the announcement on February 27, 2025 of the appointment of Joe Ciaffoni as Chief Executive Officer of the Company”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.